The Quest for mRNA Vaccines

Area of Science:

• Biotechnology
• Immunology
• Molecular Biology

Background:

• Messenger RNA (mRNA) was historically considered chemically unstable for therapeutic use, facing significant skepticism.
• Over 30 years of research, including pivotal work by Kariko and Weissman, paved the way for mRNA vaccine development.
• Early therapeutic applications of mRNA faced challenges in clinical development and scalability.

Purpose of the Study:

• To review the historical development and therapeutic potential of messenger RNA (mRNA).
• To highlight key studies demonstrating mRNA's efficacy as a therapeutic agent.
• To trace the evolution from early dendritic cell-based mRNA therapies to modern direct mRNA injection protocols.

Main Methods:

• Review of seminal studies and clinical trials involving mRNA therapeutics.
• Analysis of the progression from *in vitro* transfection of dendritic cells (DCs) to direct patient administration.
• Examination of the challenges and breakthroughs in mRNA delivery and application.

Main Results:

• Initial studies showed *in vitro* mRNA-transfected dendritic cells inhibited tumor growth in mice.
• First-in-human clinical trials utilized patient-specific DCs-mRNA for cancer vaccines.
• Despite challenges with personalized cell therapies, these findings spurred further innovation in mRNA delivery.

Conclusions:

• Messenger RNA (mRNA) has proven to be a viable and revolutionary therapeutic modality.
• Early dendritic cell-based mRNA therapies provided critical proof-of-concept and motivation for further research.
• The development of direct mRNA injection protocols culminated in highly effective COVID-19 mRNA vaccines, showcasing mRNA's broad applicability.